Montag A & Associates Inc. Invests $2.23 Million in Charles River Laboratories International, Inc. (NYSE:CRL)

Montag A & Associates Inc. bought a new position in Charles River Laboratories International, Inc. (NYSE:CRL) in the first quarter, HoldingsChannel reports. The fund bought 8,221 shares of the medical research company’s stock, valued at approximately $2,227,000.

Several other hedge funds have also added to or reduced their stakes in CRL. VisionPoint Advisory Group LLC grew its stake in Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 74 shares during the period. Brown Brothers Harriman & Co. lifted its stake in shares of Charles River Laboratories International by 76.0% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after buying an additional 95 shares in the last quarter. Sunbelt Securities Inc. grew its holdings in shares of Charles River Laboratories International by 1,072.7% during the first quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after buying an additional 236 shares during the last quarter. Concord Wealth Partners increased its position in shares of Charles River Laboratories International by 362.5% during the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock worth $70,000 after acquiring an additional 203 shares in the last quarter. Finally, GAMMA Investing LLC bought a new position in Charles River Laboratories International in the 4th quarter valued at about $62,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $226.97, for a total value of $295,968.88. Following the sale, the executive vice president now directly owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

CRL has been the topic of a number of recent analyst reports. Robert W. Baird dropped their price target on shares of Charles River Laboratories International from $271.00 to $239.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 10th. TD Cowen decreased their price objective on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a report on Monday, May 13th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, June 14th. The Goldman Sachs Group assumed coverage on Charles River Laboratories International in a report on Thursday, June 6th. They set a “buy” rating and a $290.00 target price for the company. Finally, Barclays began coverage on Charles River Laboratories International in a research report on Friday, June 28th. They set an “equal weight” rating and a $230.00 price objective on the stock. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and an average price target of $252.29.

Charles River Laboratories International Trading Up 0.7 %

Shares of CRL traded up $1.44 during trading hours on Monday, reaching $217.63. 120,568 shares of the company traded hands, compared to its average volume of 533,048. The firm has a market cap of $11.21 billion, a price-to-earnings ratio of 25.43, a PEG ratio of 2.05 and a beta of 1.38. The stock’s fifty day moving average price is $214.47 and its 200 day moving average price is $230.63. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.05 by $0.22. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).